An exploratory study published in the Journal of the Neurological Sciences reports that GLP-1 levels measured within 24 hours of a traumatic brain injury were associated with inflammation and two-week symptom scores, but only in participants with obesity. The authors describe the findings as preliminary.
GLP-1, or glucagon-like peptide-1, is the gut hormone that the weight-loss drug class imitates. Here it was not given as a drug: researchers measured what patients produced on their own after a head injury, then looked at whether those levels lined up with how people were doing two weeks later.
How the levels split
Of the 55 participants, 38.2 percent (n = 21) had an obese BMI. After controlling for age, biological sex, race and prior TBI history, that group had GLP-1 levels 21.4 percent higher within 24 hours of injury (log-estimate 0.19, 95% CI 0.003 to 0.386, p = 0.051) and 31.2 percent higher at two weeks (log-estimate 0.27, 95% CI -0.01 to 0.55, p = 0.063).
Neither of those differences cleared conventional significance, which the write-up does not hide. They are the backdrop to the more striking part of the analysis rather than the headline result.
The inflammation link
In the obesity group, GLP-1 at 24 hours was associated with interleukin-6 at two weeks (r = 0.85, p = 0.014), on just 12 participants. IL-6 is a standard inflammatory marker, and an association that tight on a sample that small is interesting and fragile in equal measure.
Symptom scores moved with it
Also in the obesity group, the change in GLP-1 from 24 hours to two weeks was inversely associated with post-concussion symptoms on the RPQ (rho = -0.84, p = 0.017), anxiety on the GAD-7 (rho = -0.74, p = 0.034) and depression on the PHQ-9 (rho = -0.86, p = 0.007). Quality of life on the QOLIBRI did not reach significance (rho = 0.70, p = 0.054), and in the 22 participants without obesity nothing was significant at all (p values 0.207 to 0.993).
Limitations
The authors call this exploratory, and the numbers justify the label: the inflammation correlation rests on 12 people, several of the group differences sit just above the significance threshold, and these are correlations, not evidence that GLP-1 is doing anything to recovery. Two weeks is also a short window for traumatic brain injury outcomes.
A biomarker, not a treatment
What the authors conclude is narrow: a link between GLP-1, IL-6 and clinical response to TBI in patients with obesity. Whether that makes GLP-1 a useful recovery biomarker, and whether the obesity split holds in a larger cohort, is exactly what this study cannot answer.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.